Allison M Bock

9PUBLICATIONS

60CO-AUTHORS

Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Jun 09, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

|Apr 27, 2026

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

|Dec 17, 2025

Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis.

Taylor J Loftus, Jeong-Yeon Cho, Manuel Meraz

|Jul 12, 2025

Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.

Janek S Walker, Kerstin Wenzl, Joseph P Novak

|Nov 29, 2024

Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.

Allison M Bock, Kerstin Wenzl, Joseph P Novak

|Aug 27, 2024

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.

Narendranath Epperla, Adam S Zayac, Daniel J Landsburg

Pageof 2

Frequent Collaborators

Thomas E Witzig

Matthew J Maurer

James R Cerhan

Umar Farooq

Yucai Wang

Narendranath Epperla

Melissa A Hopper

Stephen M Ansell

Thomas M Habermann

Grzegorz S Nowakowski

Frequent Collaborators

Thomas E Witzig

Matthew J Maurer

James R Cerhan

Umar Farooq